Protagonist Therapeutics (NASDAQ: PTGX) announced that Takeda received U.S. Food and Drug Administration approval for MIMRYLO (rusfertide), a subcutaneously administered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA